Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19

• Type of Material: Article
• Authors: Christina Fournier, Emory University; Marinella D Galea, James J Peters VAMC; Vicent P Galea, The Icahn School of Medicine at Mount Sinai; Adam C Eberhart, VA St Louis Medical Center John Cochran Division; Huned S Patwa, Yale University; Ileana Howard, VA Puget Sound Healthcare System; Richard S Bedlack, Duke University
• Language: English
• Date: 2021-07-30
• Publisher: WILEY
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Wiley Periodicals LLC
• Final Published Version (URL): http://dx.doi.org/10.1002/mus.27373
• Title of Journal or Parent Work: MUSCLE & NERVE
• Volume: 64
• Issue: 4
• Start Page: E18
• End Page: E20
• Keywords: Neurosciences; Science & Technology; Clinical Neurology; Neurosciences & Neurology; Life Sciences & Biomedicine

Abstract

Approximately 16,000 persons in the United States are affected by amyotrophic lateral sclerosis (ALS). 1 Persons with ALS (PALS) have distinctive pathophysiological risks and health determinants that may increase their vulnerability for infection with severe‐acute‐respiratory‐syndrome‐associated‐coronavirus (SARS‐CoV‐2) and severe Coronavirus‐2019 (COVID‐19) outcome.2, 3 Data on the prevalence and impact of COVID‐19 in this population is scarce. 4